Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sabatolimab (Primary) ; Azacitidine; Azacitidine; Decitabine; Infliximab; Tocilizumab
Indications Myelodysplastic syndromes
Focus Registrational; Therapeutic Use
Acronyms STIMULUS-MDS1
Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

08 Apr 2025 Status changed from completed to discontinued.
04 Sep 2024 Status changed from active, no longer recruiting to completed.
31 Aug 2024 This trial has been Discontinued in Austria (Global end date: 2024-07-15), According to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com